Case Report

Primary melanocytic tumors of the central nervous system: Report of two cases and review of literature

Victoria Trinh, Rafael Medina-Flores¹, Chistopher L. Taylor, Howard Yonas, Muhammad O. Chohan

Department of Neurosurgery, University of New Mexico, Albuquerque, New Mexico, ¹Department of Neuropathology, Marshfield Clinic, Marshfield, Wisconsin, USA

E-mail: Victoria Trinh - victoria.t.trinh@gmail.com; Rafael Medina-Flores - rafael.medinaflores@gmail.com; Chistopher L. Taylor - ctaylor@salud.unm.edu; Howard Yonas - hyonas@salud.unm.edu; *Muhammad O. Chohan - mchohan@salud.unm.edu

*Corresponding author

Received: 30 March 14  Accepted: 11 August 14  Published: 13 October 14

This article may be cited as: Trinh V, Medina-Flores R, Taylor CL, Yonas H, Chohan MO. Primary melanocytic tumors of the central nervous system: Report of two cases and review of literature. Surg Neurol Int 2014;5:147.

Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2014/5/1/147/142795

Copyright: © 2014 Trinh V. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Primary melanocytic tumors of the central nervous system (CNS) represent only 1% of all melanomas. We report two rare cases of primary diffuse leptomeningeal melanomatosis (PDLM; case 1) and primary melanoma of the thoraco-lumbar spine (case 2).

Case Description: In case 1, multiple cerebrospinal fluid (CSF) studies and a brain biopsy were non-diagnostic, with a biopsy of the cauda equina eventually demonstrating malignant melanomatosis. Diagnosis of primary spinal cord melanoma was more straightforward in case 2 with imaging and biopsy.

Conclusion: PDLM and primary intramedullary spinal melanoma are rare variants of primary CNS melanoma. This report contrasts the diagnostic challenges between the two entities and alerts the neurosurgeon into considering the diagnosis with appropriate clinical presentation.

Key Words: CNS melanocytic tumors, diffuse leptomeningeal melanomatosis, primary CNS melanoma

INTRODUCTION

Although metastatic melanoma is the third most common etiology of central nervous system (CNS) metastasis, primary melanocytic tumors of the CNS are rare and account for only 1% of all melanomas.¹ These lesions arise from melanocytes located within the leptomeninges, and can occur as diffuse or solitary, benign or malignant.¹⁴ Studies on primary CNS melanocytic lesions are few and limited to case reports or small case series.¹¹ In order to illustrate the clinical spectrum of primary melanocytic tumors of the CNS, we present two rare cases: (1) primary diffuse leptomeningeal melanomatosis (PDLM) and (2) primary thoraco-lumbar spinal melanoma. We also review the literature for clinical, radiological, surgical, and histological findings of these lesions.

CASE REPORTS

Case 1: PDLM
Clinical summary
A 51-year-old male presented with progressive headaches, nausea, vomiting, left hip pain, and fatigue for 3 weeks. Neurological examination showed left leaning talipic gait and difficulty with tandem and heel-to-toe walking. Brain magnetic resonance...
imaging (MRI) showed extensive leptomeningeal enhancement with a small focus of nodular parenchymal enhancement [Figure 1a and b], and non-specific T2 white matter hypointensities [Figure 1c]. Cerebrospinal fluid (CSF) workup was suggestive of aseptic meningoencephalitis (lymphocyte predominance with elevated total protein and IgG). Over the next week, he had decreasing lower extremity strength. A repeat lumbar puncture (LP) revealed opening pressure of 45, with elevated protein level. Brain MRI was unchanged while spine MRI showed diffuse leptomeningeal nodular enhancement of the cervical, thoracic, and cauda equina nerve roots [Figure 1d–f]. The patient was started on empiric treatment for CNS fungal disease, while CSF serology and culture were pending. Multiple therapeutic LPs were performed during the hospital course with similar abnormal CSF profiles (persistently elevated total nucleated cells and protein, low glucose), but were ultimately non-diagnostic. A right temporal brain biopsy was then performed. Surgical pathology was initially concerning for *Nocardia asteroides* that was later determined as a contaminant. The patient’s neurological status continued to deteriorate with intermittent leg weakness and episodes concerning clinical seizures.

Owing to diagnostic dilemma and patient’s deteriorating condition, a cauda equina biopsy was performed 3 weeks after the brain biopsy. Frozen section of the nerve root demonstrated pigmented cells, and final surgical pathology revealed primary leptomeningeal melanomatosis [Figure 2]. Tumor cells were strongly immunoreactive for HMB-45 and MART-1, with a high Ki-67 proliferation index. Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG-18 PET CT) demonstrated absence of abnormal FDG activity outside the CNS.

The patient underwent palliative cranio-spinal radiation treatment with adjuvant Temozolomide. These were poorly tolerated and were discontinued after a month. Three months from initial presentation, he died from cardiopulmonary failure.

**Case 2: Primary thoraco-lumbar spinal cord melanoma**

**Clinical summary**

A 75-year-old female presented with 3 months of gradually worsening back pain, along with a week-long history of right foot drop, bilateral lower extremity weakness, tripping and falling without bowel or bladder symptoms. Spinal MRI showed an expansile

---

*Figure 1: Brain MRI (a–c) showing diffuse areas of FLAIR signal changes (a) and T1W post-gadolinium sequence with diffuse leptomeningeal and nodular parenchymal enhancement (b, arrow) and cranial nerve enhancement (c, arrow showing CNIII). Post-contrast scan of cervical (d) and thoracic (e) spine showing diffuse nodular leptomeningeal enhancement. This was most significant at the lower lumbar region with almost complete obliteration of normal CSF signal on T2WI (f)*
intramedullary mass involving the lower thoracic spinal cord and the conus medullaris from T11 to L1, isointense on T1-weighted imaging, and homogenously enhancing following gadolinium injection [Figure 3].

The patient underwent surgical resection of the mass. Pathology revealed a highly cellular tumor with spindle cell morphology and abundant dark pigmentation [Figure 4]. Prominent nucleoli, intranuclear pseudo-inclusions, and mitotic figures were present. Immunohistochemistry staining was positive for melanoma markers S100, MART-1, and HMB-45 and negative for epithelial membrane antigen (EMA) and BRAF V600E mutation.

She remained paraparetic postoperatively with no new deficits. Staging workup, including MRI, PET, and ophthalmology evaluation, was negative for evidence of additional disease. She was discharged to a rehabilitation center for physical and occupational therapy. During her last clinic visit, she reported improving sensation in bilateral lower extremities. She is currently undergoing radiotherapy at an outside hospital.

**DISCUSSION**

**Origins**

Melanocytes, pigment-producing cells of neural crest origin, migrate during development to the skin, eyes, oro-genital mucosa, and leptomeninges. Melanomas predominately develop in the skin, but infrequently primary melanocytic lesions of the CNS may originate from melanocytes in the leptomeninges that undergo transformation. The World Health Organization in 2007 sub-classified primary melanocytic lesions into malignant melanoma, melanomatosis, melanocytoma, and diffuse melanocytosis. These lesions are typically located in the perimedullary and high cervical region, and uncommonly, like in our cases, in the thoraco-lumbar spinal cord and cauda equina.

**Clinical presentation**

**PDLM of the CNS**

PDLM (first case) is a rare variant of primary malignant melanoma, occurring more often in adults than in children. To the best of our knowledge, there are only seven cases [Table 1] of this lesion reported in the literature, which is distinguished from diffuse melanosis or melanocytosis by the presence of malignant features. PDLM occurs in patients with age ranging from 20 to 70 years (mean 42 years). PDLM invades brain parenchyma in all cases, with reported involvement of the spinal cord in 43% of cases, of which two cases (67%) have been reported in the cervical thoracic region and one case (33%) in the lower thoracic region with involvement of the cauda equina. The most common presenting symptoms of PDLM include headache (46%), nausea or vomiting (37%), back or neck pain (24%), and weakness (22%). Other clinical features include hydrocephalus, seizure, ataxia, syringomyelia, cranial nerve palsies, intracranial hemorrhage, and neuropsychiatric symptoms. The clinical features of PDLM versus other primary meningeal lesions are presented in Table 2.

**Primary melanoma of the CNS**

Primary CNS melanomas (second case) occur in patients with age ranging from 20 to 80 years (mean 54 years), with a peak in the fifth decade. In the spinal cord, they most commonly occur in the thoracic region (42%), followed by cervical (35%), thoraco-lumbar (12%), cervicothoracic (8%), and lumbar (4%) regions. Whereas life expectancy is less than 1 year in patients with metastatic melanoma to the CNS, a subgroup of patients with primary CNS melanoma in the literature...
report an average survival of 7 years\(^{9,10}\) after gross total resection. Therefore, differentiating between primary and metastatic melanoma may be important for prognosis.

**Diagnosis**

**Neuroimaging**

Due to the paramagnetic properties of melanin, melanocytic lesions are isointense or hyperintense on T1-weighted imaging, hypointense on T2-weighted imaging,\(^4,16\) and demonstrate intense enhancement with gadolinium.\(^{16}\) These characteristics vary depending on the melanocytic content and hemorrhage. Because the radiographic features are nonspecific, the differential diagnosis is extensive, including infectious conditions and metastatic carcinoma. Therefore, to establish the diagnosis, imaging must be supplemented with CSF studies and histopathology (when the CSF studies are inconclusive but a melanocytic lesion is strongly suspected).\(^{15}\) PDLM has a tendency to appear as diffuse meningeal thickening on CT and MRI, whereas primary melanoma appears dense and nodular.\(^{16}\) No distinguishing imaging characteristics separate primary malignant melanoma from metastatic melanoma; therefore, careful examination for the presence of melanoma elsewhere is necessary to exclude a primary lesion.

**Primary diffuse leptomeningeal melanomatosis**

**Lumbar puncture.** The diagnosis of PDLM is notoriously difficult to make.\(^2,13,15\) Clinically, PDLM can mimic a wide variety of other conditions, including lymphoma, metastatic carcinoma, viral encephalitis, and bacterial and fungal meningitis. The diagnosis can be established with identification of melanocytes on cytological examination of CSF.\(^{17}\) However, the utility of CSF is dependent on the number and degree of pigmentation of cells. Isolated neoplastic cells in the

---

**Table 1: Literature review: PDLM**

| Study          | Pub year | Sex/age | Presenting symptoms | Site                           | MRI dx | CSF dx             | Histo dx            | Chemo | Rad | Other interv | Survival            |
|----------------|----------|---------|---------------------|-------------------------------|--------|-------------------|---------------------|-------|-----|-------------|---------------------|
| Gaetani et al. | 1993     | 22/F    | L iliac pain, bilateral motor weakness | Brain, cervical, thoracic     | Yes    | No                | Yes                 | No    | No | No | >8 months |
| Celli et al.   | 2001     | 53/M    | Psychastenia, amnesia | Brain                         | Yes    | Inconclusive, no malignant cells | No          | No    | No | No | Not reported |
| Pirini et al.  | 2003     | 68/F    | Headache, vomiting, mental deterioration | Brain                         | Yes    | No neoplastic cells | No                  | No    | No | No | 3 years   |
| Demir et al.   | 2008     | 32/M    | Headache, vomiting, complex partial seizure | Brain, cervical, thoracic spine | Yes    | Inconclusive, no malignant cells | Postmortem + S-100, +vimentin, +HMB-45 | No    | No | VP shunt | 1 week |
| Liubinas et al.| 2010     | 43/M    | Progressive headache, drowsiness, confusion | Brain                         | Yes    | OP protein, atypical cells, no malignant cells | Yes + S-100, +vimentin, +tyrosinase | No    | No | VP shunt, serial LPs, decadron | “Few days” |
| Zadro et al.   | 2010     | 34/M    | Papilledema, flaccid leg, weakness, cognitive impairment | Brain, thoracic spine cauda equina | Yes    | WBC (lymphocytes), protein, glucose, no malignant cells | Yes + Melanin-A, +HMB-45, +vimentin | No    | Yes | No | 2 months after radiation |
| Arias et al.   | 2011     | 40/F    | Subacute headaches, visual impairment, meningismus | Brain                         | Yes    | Protein, no malignant cells | Yes                 | No    | No | No | Not reported |
| Current study  | NA       | 51/M    | Progressive headache, fatigue, imbalance | Brain, cervical, thoracic, lumbar spine | Yes    | WBC (lymphocytes), protein, glucose, no malignant cells | Yes, not tolerated | Yes   | No | 3 months after presentation |

Pub: Publication year, dx: Diagnosis, histo: Histology, chemo: Chemotherapy, rad: Radiation, interv: Other intervention, sv: Survival, L: Left, R: Right, OP: Opening pressure, F: Female, M: Male
Table 2: Distinguishing clinical features between malignant melanoma, melanomatosis, melanocytoma, diffuse melanocytosis

|                        | Primary CNS melanoma | PDLM | Melanocytoma | Diffuse melanocytosis |
|------------------------|----------------------|------|--------------|-----------------------|
| Age                    | 15-71 years, peak 5th decade | 20-70 years | 9-73 years old, peak 5th decade | <10 years or 10-30 years |
| Incidence              | 0.005 cases per 100,000 | Very rare, unknown | 1 per 10 million | Unknown |
| Sex                    | 1:1 male: Female | 1:1 male: Female | Female predominance | Male predominance |
| No. lesions            | Solitary but may metastasize | Extensive | Solitary or multiple | Extensive |
| Area of occurrence     | Predilection for posterior fossa and spinal cord: Thoracic, cervical, thoracolumbar | Parenchymal, thoracic, less commonly cervical and cauda equina | Cervical, thoracic spine usually intradural, extramedullary | Supra-and infra-tentorial leptomeninges, cerebellum, pons, medulla, temporal lobes |
| Brain involvement      | Brain and/or spine | Always | No | No |
| Extra-neural disease   | May metastasis. Association with neurocutaneous melanosis | No | Melanotic lesions to kidneys, adrenal glands | Association with neurocutaneous syndromes, neurofibromatosis-1, Sturge-Weber syndrome, Dandy Walker syndrome |

Clinical symptoms
- Intracranial hypertension, hydrocephalus, focal deficits from compression, SAH, seizure
- Headache, weakness, cognitive impairment
- Intracranial hypertension or hemorrhage, neuropsychiatric, spinal cord compression, seizures
- Intradural hypertension, hydrocephalus, seizure, ataxia, syringomyelia, cranial nerve palsy

Clinical course
- Aggressive
- May be aggressive, 71% recurrence within 5 years
- No definitive treatment.
- Aggressive
- Tumor debulking and VP shunt insertion palliative. Role of chemo and radiation unclear

Treatment
- Total resection, postoperative radiotherapy
- No definitive treatment, VP shunt is palliative
- Total resection, adjuvant radiotherapy. Preliminary results positive with intrathecal chemotherapy
- No definitive treatment.

Prognosis
- Better with total resection versus partial resection. Average survival after surgery and radiotherapy 6 years and 7 months
- Poor
- Recurrence common at 5 years
- Poor

PDLM: Primary diffuse leptomeningeal melanomatosis, CNS: Central nervous system, VP: Ventriculoperitoneal, SAH: Subarachnoid hemorrhage

CSF may not be present in a sample or can escape recognition.[15] In our case, despite multiple (six) LPs sent for cytology, neither malignant cells nor melanin-containing cells were identified. Non-specific but abnormal CSF findings concerning chronic aseptic meningitis (elevated opening pressure, high protein, low glucose) further delayed diagnosis. In a review of PDLM cases reported in the literature [Table 1], diagnosis could only be established after biopsy or postmortem (in two cases), with CSF studies being non-diagnostic. Histopathological diagnosis was obtained from cerebral biopsy in four cases, from spinal biopsy in one case, and from cerebral autopsy in two cases. Our case is unique among other PDLM cases in that initial brain biopsy was negative, requiring biopsy of cauda equina for the final diagnosis. This case highlights the variability of neoplastic cells in CSF and tissue, and the difficulty in reaching this diagnosis, requiring repeat biopsy.

**Surgical appearance and histopathology**

Biopsy is often the only definitive diagnostic procedure in cases of suspected PDLM in which CSF analysis and neuroimaging are inconclusive, such as in case 1. Biopsy is performed much less frequently than LP or neuroimaging due to associated risks, and may not be considered indicated in cases where CSF cytology is negative.[15] We believe that repeat LP and/or biopsy may be indicated for cases where CSF studies are persistently abnormal in the absence of malignant cells, whose presence may be variable.

Dense sheets of pleomorphic, spindle-shaped cells with melanin are typical histological findings.[16] In contrast to melanocytoma, PDLM diffusely infiltrates the leptomeninges, and unlike diffuse melanosis, demonstrates features of malignancy.[15] PDLM, similar to other primary melanocytic lesions, is usually immunoreactive for anti-melanoma antibody (HMB-45), anti-melanominal antibody MART-1 (Melan-A), and tyrosinase,[11] and is variably reactive with vimentin and S-100 protein.[11] Unlike melanin containing meningioma, melanocytic lesions do not demonstrate immunoreactivity for EMA.[18] Some of the distinguishing features of the different types of melanocytic lesions involving the CNS are detailed in Table 2.

**Primary CNS melanoma**

Surgical appearance and histopathology
Intraoperatively, primary malignant melanoma may appear as a solid, darkly pigmented tumor with varying
amounts of hemorrhage.\textsuperscript{[16]} Immunohistochemistry findings are similar to other melanocytic lesions.\textsuperscript{[11]} The diagnosis of primary CNS melanoma relies on imaging and biopsy, and less on CSF studies, in which extensive dissemination in CSF may not have occurred. The dense appearance of melanoma may provide a more accessible target for successful biopsy than a diffuse process such as PDLM or diffuse melanocytosis.

**CONCLUSION**

To conclude, PDLM and primary CNS melanoma are rare tumors that present a diagnostic and therapeutic challenge to the neurosurgeon and oncologist. We emphasize the difficulty of establishing a diagnosis of PDLM through CSF cytology and imaging alone. The presence of neoplastic cells may be highly variable in CSF and in tissue samples. Because of the diffuse appearance of PDLM versus the more dense appearance of primary CNS melanoma, in some cases, repeat biopsy may be needed to establish the diagnosis. Our understanding of these tumors relies on a small number of reported cases; thus diagnosis and management are not standardized. Diagnosis of this condition requires a high index of suspicion and familiarity with the clinical, CSF, and radiographic findings. This condition can mimic other causes of chronic aseptic meningitis, and biopsy may be the only definitive diagnosis when radiographic and CSF findings are inconclusive.

**REFERENCES**

1. Arias M, Alberte-Woodward M, Arias S, Dapena D, Prieto A, Suarez-Penaranda JM. Primary malignant meningeal melanomatosis: A clinical, radiological and pathologic case study. Acta Neurol Belg 2011;111:228-31.
2. Brunsvig KL, Zenobi M, Rilliet B, El Hassani Y, de Haller R, Ansari M, et al. Primary leptomeningeal melanocytosis in a 10-year-old girl: A challenging diagnosis with a poor prognosis. J Child Neurol 2011;26:1444-8.
3. Celli P, Acqui M, Trillo G, Ramundo EO, D’Andrea G, Roperto R, et al. Primary leptomeningeal melanocytosis: Early leptomeningeal enhancement on MRI. J Neurosurg Sci 2001;45:235-40.
4. Demir MK, Aker FV, Akinci O, Oztugtekin A, Case 134: Primary leptomeningeal melanomatosis. Radiology 2008;247:905-9.
5. Farrokhi D, Fransen P, Faverly D. MR findings of a primary intramedullary malignant melanoma: Case report and literature review. AJNR Am J Neuroradiol 2001;22:1864-6.
6. Gaetani P, Martelli A, Sessa F, Zappoli F, Rodriguez R, Baena. Diffuse leptomeningeal melanomatosis of the spinal cord: A case report. Acta Neurochir 1993;121:206-11.
7. Harstad L, Hess KR, Groves MD. Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro Oncol 2008;10:1010-8.
8. Jaiswal S, Vij M, Tringia A, Jaiswal AK, Srivastava AK, Behari S. Primary melanocytic tumors of the central nervous system: A neuroradiological and clinicopathological study of five cases and brief review of literature. Neurol India 2011;59:413-9.
9. Kim MS, Yoon do H, Shin DA. Primary spinal cord melanoma. J Korean Neurosurg Soc 2010;48:57-61.
10. Larson TC 3rd, Houser OW, Onofrio BM, Piegras DG. Primary spinal melanoma. J Neurosurg 1987;66:47-9.
11. Liubinas SV, Maartens N, Drummond KJ. Primary melanocytic neoplasms of the central nervous system. J Clin Neurosci 2010;17:1227-32.
12. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. J Clin Neurosci 2010;17:119-54.
13. Michael BD, Syndikus I, Clark A, Baborie A. Diffuse primary leptomeningeal melanocytosis in a patient receiving a novel cancer cell vaccine for prostate cancer: BMJ Case Rep 2010;2010. pii: bcr1120092495. doi: 10.1136/bcr.11.2009.2495.
14. Nikola Z, Dragan M, Mijovic Z, Milentjevic MJ. Primary leptomeningeal melanocytosis--a case report with an autopsy diagnosis. Vojnosanit Pregl 2012;69:631-4.
15. Pirini MG, MasciaU M, Salvi F, Tassinari CA, Zanella L, Bacchini P, et al. Primary diffuse meningeal melanomatosis: Radiologic-pathologic correlation. AJNR Am J Neuroradiol 2003;24:115-8.
16. Smith AB, Rushing EJ, Smirniotopoulos JG. Pigmented lesions of the central nervous system: Radiologic-pathologic correlation. Radiographics 2009;29:1503-24.
17. Tosaka M, Tamura M, Oriuchi N, Horikoshi M, Joshua T, Sugawara K, et al. Cerebrospinal fluid immunocytochemical analysis and neuroimaging in the diagnosis of primary leptomeningeal melanoma. Case report. J Neurosurg 2001;94:328-32.
18. Uematsu Y, Yokote Y, Itaku T, Hayashi Y, Komai N. Meningeal melanocytoma: Magnetic resonance imaging characteristics and pathological features. Case report. J Neurosurg 1992;76:705-9.
19. Wadasadawala T, Trivedi S, Gupta T, Epari S, Jalali R. The diagnostic dilemma of primary central nervous system melanoma. J Clin Neurosci 2010;17:1014-7.
20. Zadro I, Brinar VV, Barun B, Ozretic D, Pazanin L, Grahovac G, et al. Primary diffuse meningeal melanomatosis. Neurologist 2010;16:117-9.